Altered glutamyl-aminopeptidase activity and expression in renal neoplasms

BMC Cancer

Lorena Blanco¹  Begoña Sanz¹  Itxaro Perez⁴  Clara E Sánchez⁴  M Luz Cándenas³  Francisco M Pinto³  Javier Gil¹  Luis Casis¹  José I López²  Gorka Larrinaga⁴ 

[1] Department of Physiology, Faculty of Medicine and Dentistry, Universitiy of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain

[2] Department of Anatomic Pathology, Cruces University Hospital, University of the Basque Country (UPV/EHU), Barakaldo, Bizkaia, Spain

[3] Institute for Chemical Research, CSIC, Sevilla, Spain

[4] Department of Nursing I, Faculty of Nursing, Universitiy of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain

关键词: Renal neoplasm;    Clear cell renal cell carcinoma;    Angiotensin;    Angiotensinase;    Aminopeptidase A;    Glutamyl-aminopeptidase;   

Others  :  858765
DOI  :  10.1186/1471-2407-14-386

 received in 2013-06-23, accepted in 2014-05-08,  发布年份 2014

【 摘 要 】

Background

Advances in the knowledge of renal neoplasms have demonstrated the implication of several proteases in their genesis, growth and dissemination. Glutamyl-aminopeptidase (GAP) (EC. 3.4.11.7) is a zinc metallopeptidase with angiotensinase activity highly expressed in kidney tissues and its expression and activity have been associated wtih tumour development.

Methods

In this prospective study, GAP spectrofluorometric activity and immunohistochemical expression were analysed in clear-cell (CCRCC), papillary (PRCC) and chromophobe (ChRCC) renal cell carcinomas, and in renal oncocytoma (RO). Data obtained in tumour tissue were compared with those from the surrounding uninvolved kidney tissue. In CCRCC, classic pathological parameters such as grade, stage and tumour size were stratified following GAP data and analyzed for 5-year survival.

Results

GAP activity in both the membrane-bound and soluble fractions was sharply decreased and its immunohistochemical expression showed mild staining in the four histological types of renal tumours. Soluble and membrane-bound GAP activities correlated with tumour grade and size in CCRCCs.

Conclusions

This study suggests a role for GAP in the neoplastic development of renal tumours and provides additional data for considering the activity and expression of this enzyme of interest in the diagnosis and prognosis of renal neoplasms.

【 授权许可】

   
2014 Blanco et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
• [2]López-Beltrán A, Scarpelli M, Montironi R, Kirkali Z: 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006, 49(5):798-805.
• [3]Schuetz NA, Yin-Goen Q, Amin MB, Moreno CS, Cohen C, Hornsby CD, Yang WL, Petros JA, Issa MM, Pattaras JG, Ogan K, Marshall FF, Young AN: Molecular classification of renal tumors by gene expression profiling. J Mol Diagn 2005, 7(2):206-208.
• [4]Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS: Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005, 173(6):1853-1862.
• [5]Jin JS, Hsieh DS, Lin YF, Wang JY, Sheu LF, Lee WH: Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol 2006, 13(5):573-580.
• [6]Patraki E, Cardillo MR: Quantitative immunohistochemical analysis of matrilysin 1 (MMP-7) in various renal cell carcinoma subtypes. Int J Immunopathol Pharmacol 2007, 20(4):697-705.
• [7]Catania JM, Chen G, Parrish AR: Role of matrix metalloproteases in renal pathophysiologies. Am J Physiol Renal Physiol 2007, 292(3):905-911.
• [8]Göhring B, Holzhausen HJ, Meye A, Heynemann H, Rebmann U, Langner J, Riemann D: Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. Int J Mol Med 1998, 2(4):409-414.
• [9]Nanus DM, Bogenrieder T, Papandreou CN, Finstad CL, Lee A, Vlamis V: Aminopeptidase A expression and enzymatic activity in primary human renal cancers. Int J Oncolology 1998, 13(2):261-267.
• [10]Varona A, Blanco L, López JI, Gil J, Agirregoitia E, Irazusta J, Larrinaga G: Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am J Physiol Renal Physiol 2007, 292(2):780-788.
• [11]Blanco L, Larrinaga G, Pérez I, López JI, Gil J, Agirregoitia E, Varona A: Acid, basic and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma. Am J Physiol Renal Physiol 2008, 294(4):850-858.
• [12]Varona A, Blanco L, Perez I, Gil J, Irazusta I, Lopez JI, Candenas ML, Pinto FM, Larrinaga G: Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer 2010, 10:193. BioMed Central Full Text
• [13]Wolf G, Mentzel S, Assmann KJ: Aminopeptidase A: a key enzyme in the intrarenal degradation of angiotensin II. Experimental Nephrolology 1997, 5(5):364-369.
• [14]Dijkman HB, Assmann KJ, Steenbergen EJ, Weltzels JF: Expression and effect of inhibition of aminopeptidase-A during nephrogenesis. J Histochemestry and Cytochemestry 2006, 54(2):253-262.
• [15]Bander NH, Cordon-Cardo C, Finstad CL, Whitmore WF, Vaughan ED, Oettgen HF, Melamed M, Old LJ: Immunohistologic dissection of the human kidney using monoclonal antibodies. J Urol 1985, 133(3):502-505.
• [16]Nanus DM, Engelstein D, Gastl GA, Gluck L, Vidal MJ, Morrison M, Finstad C, Bander NH, Albino AP: Molecular cloning of the human kidney differentiation antigen gp160: Human aminopeptidase A. Proc Natl Acad Sci U S A 1993, 90(15):7069-7073.
• [17]Kehlen A, Göhring B, Langer J, Riemann D: Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 in renal carcinoma cells and renal tubular epithelial cells by cytokines ans cAMP-increasing mediators. Clin Exp Immunol 1998, 111(2):435-441.
• [18]Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP: Antiproliferative and antitumor effects of alpha interferon in renal cell carcinomas: correlation with the expression of a kidney associated differentiation glycoprotein. Cancer Res 1990, 50(14):4190-4194.
• [19]Sobin LH, Wittekind C: TNM Classification of Malignant Tumors. 6th edition. New York: Wiley-Liss; 2002.
• [20]Furhman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6(7):655-663.
• [21]Martínez JM, Prieto I, Ramírez MJ, Cueva C, Alba F, Ramírez M: Aminopeptidase activities in breast cancer tissue. Clin Chem 1999, 45(10):1797-1802.
• [22]Ramírez-Expósito MJ, Martínez JM, Prieto I, Alba F, Ramírez M: Comparative distribution of glutamyl and aspartyl aminopeptidase activities in mouse organs. Horm Metab Res 2000, 32(5):161-163.
• [23]Ramírez M, Prieto M, Alba F, Vives F, Banegas I, de Gasparo M: Role of central and peripheral aminopeptidase activities in the control of blood pressure: a working hypothesis. Heart Fail Rev 2008, 13(3):339-353.
• [24]Tobe H, Kojima F, Aoyagi T, Umezawa H: Purification using amastatin and properties of aminopeptidase A from pig kidney. Biochimica Biophysica Acta 1980, 613(2):459-468.
• [25]Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
• [26]Patak E, Candenas ML, Pennefather JN, Ziccone S, Lilley A, Martín JD, Flores C, Flores C, Mantecón AG, Story ME, Pinto FM: Tachykinins and tachykinin receptors in human uterus. Br J Pharmacol 2003, 139(3):523-532.
• [27]Rozen S, Skaletsky H: Primers on the WWW for general users and for biologist programmers. Methods Mol Biol 2000, 132:365-368.
• [28]Jung M, Ramankulov A, Roigas J, Johannsen M, Ringsdorf M, Kristiansen G, Jung K: In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol 2007, 8:47. BioMed Central Full Text
• [29]Radonic A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A: Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 2004, 313(4):856-862.
• [30]Pinto FM, Almeida TA, Hernandez M, Devillier P, Advenier C, Candenas ML: mRNA expression of tachykinins and tachykinin receptors in different human tissues. Eur J Pharmacol 2004, 494(2–3):233-239.
• [31]Antczak C, De Meester I, Bauvois B: Ectopeptidases in pathophysiology. Bioessays 2001, 23(3):251-260.
• [32]Carl-McGrath S, Lendeckel U, Ebert M, Röcken C: Ectopeptidases in tumour biology: a review. Histol Histopathol 2006, 21(12):1339-1353.
• [33]Zhou M, Roma A, Magi-Galluzzi C: The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med 2005, 25(2):247-257.
• [34]Larrinaga G, Perez I, Sanz B, Blanco L, López JI, Candenas ML, Pinto FM, Gil J, Irazusta J, Varona A: Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regul Pept 2010, 165(2–3):218-223.
• [35]Blanco L, Perez I, Sanz B, Gil J, López JI, Ugalde A, Varona A, Larrinaga G: Changes in cell-surface peptidase activity in papillary renal cell carcinoma. Anticancer Res 2010, 30(4):1137-1141.
• [36]Larrinaga G, López JI, Casis L, Blanco L, Gil J, Agirregoitia E, Varona A: Cystinyl aminopeptidase activity is decreased in renal cell carcinoma. Regul Pept 2007, 144(1–3):56-61.
• [37]Larrinaga G, Blanco L, Sanz B, Perez I, Gil J, Unda M, Andrés L, Casis L, López JI: The impact of peptidase activity on clear cell renal cell carcinoma survival. Am J Physiol Renal Physiol 2012, 303(12):1584-1591.
• [38]Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Feliers D: mRNA traslation: unexplored territory in renal science. J Am Soc Nephrol 2006, 17(12):3281-3292.
• [39]Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Battle D: ACE and ACE2 activity in diabetic mice. Diabetes 2006, 55(77):2132-2139.
• [40]Ino K, Shibata K, Kajiyama H, Kikkawa F, Mizutani S: Regulatory role of membrane-bound peptidases in the progression of gynecologic malignancies. Biol Chem 2004, 385(8):683-690.
• [41]Deshayes F, Nahmias C: Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005, 16(7):293-299.
• [42]George AJ, Thomas WG, Hannan RD: The renin-angiotensin system and cancer: old dog, new trick. Nat Rev Cancer 2010, 10(11):745-759.
• [43]Marchiò S, Lahdenranta J, Schlingemann RO, Valdembri D, Wesseling P, Arap MA, Hajitou A, Ozawa MG, Trepel M, Giordano RJ, Nanus DM, Dijkman HB, Oosterwijk E, Sidman RL, Cooper MD, Bussolino F, Pasqualini R, Arap W: Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 2004, 5(2):151-162.
• [44]Re RN, Cook JL: The intracrine hypothesis: an update. Regul Pept 2006, 133(1–3):1-9.
• [45]Re RN, Cook JL: An intracrine view of angiogenesis. Bioessays 2006, 28(9):943-953.
• [46]Baker KM, Chernin MI, Schreiber T, Sanghi S, Heiderzaidi S, Booz GW, Dostal D, Kumar R: Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept 2004, 120(1–3):5-13.
• [47]Zhuo JL, Li XC: New insights and perspectives on intrarenal renin-angiotensin system: fous on intracrine/intracellular angiotensin II. Peptides 2011, 32(7):1551-1565.